Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
AMI-193Cat. No. 0524 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 8-[3-(4-Fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]-decanone |
Biological Activity
Selective 5-HT antagonist, which binds to 5-HT2 sites as potently as spiperone but has lower affinity for 5-HT2C receptors. Also a high affinity D2 receptor antagonist (Ki = 3 nM). Lacks the disruptive effect of spiperone on animal behavior.Certificate of Analysis / Safety Data Sheet
References
Ismaiel et al (1993) Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5HT2 versus 5HT1C selective antagonist. J.Med.Chem. 36 2519. PMID: 8355253.
Czoty et al (2000) Behavioural effects of AMI-193, a 5-HT2A- and dopamine D2-receptor antagonist, in the squirrel monkey. Pharmacol.Biochem.Behav. 67 257. PMID: 11124389.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: AMI-193, supplier, Selective, 5-HT2, antagonists, D2-like, receptor, Non-Selective, Serotonin, Receptors, Dopamine, dopaminergic
Quick Order
Find multiple products by catalog number
5-HT Review
Written by Nicholas Barnes and John Neumaier, leading experts. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
New Products in this Area
Selective 5-HT2A antagonist
Quetiapine hemifumarate5-HT2/D2 antagonist; atypical antipsychotic
S 32212 hydrochloride5-HT2C inverse agonist; α2 antagonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.